Hao Wen-Rui, Cheng Chun-Yao, Cheng Tzu-Hurng
Division of Cardiology, Department of Internal Medicine, Shuang Ho Hospital, Ministry of Health and Welfare, Taipei Medical University, New Taipei City 23561, Taiwan.
Division of Cardiology, Department of Internal Medicine, School of Medicine, College of Medicine, Taipei Medical University, Taipei City 11002, Taiwan.
World J Clin Cases. 2024 Oct 26;12(30):6358-6360. doi: 10.12998/wjcc.v12.i30.6358.
Inflammatory bowel disease, particularly ulcerative colitis (UC), poses significant treatment challenges due to its chronic nature and potential for severe complications. This editorial reviews a recent network meta-analysis that evaluated the efficacy of and highlighted the superior outcomes achieved by combining each of five traditional Chinese medicine (TCM) formulations with mesalazine for the adjuvant treatment of UC. Clinical outcomes included enhanced mucosal healing, improved quality of life, and reduced recurrence rates. Additionally, the combination therapy resulted in a lower incidence of adverse reactions compared with mesalazine monotherapy. Despite these promising results, limitations such as variability in study quality and TCM dosage highlight the need for further high-quality, large-sample, multicenter randomized controlled trials. This editorial underscores the potential of TCM in enhancing UC management and calls for more rigorous research to substantiate these findings and refine clinical guidelines.
炎症性肠病，尤其是溃疡性结肠炎（UC），因其慢性病程和严重并发症的潜在风险，带来了重大的治疗挑战。这篇社论回顾了一项近期的网状Meta分析，该分析评估了五种中药配方分别与美沙拉嗪联合用于UC辅助治疗的疗效，并强调了联合治疗取得的更佳结果。临床结果包括黏膜愈合增强、生活质量改善和复发率降低。此外，与美沙拉嗪单药治疗相比，联合治疗导致的不良反应发生率更低。尽管有这些令人鼓舞的结果，但研究质量和中药剂量的变异性等局限性凸显了进一步开展高质量、大样本、多中心随机对照试验的必要性。这篇社论强调了中药在改善UC管理方面的潜力，并呼吁进行更严格的研究以证实这些发现并完善临床指南。
